Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has applied to the ASX for quotation of 89,175,565 new options, carrying the code IMUOF and expiring on 30 April 2027. The options, issued on 1 May 2026 following prior placement disclosures in March, expand the company’s listed securities base and may provide additional future capital inflows as they are exercised, potentially supporting ongoing development programs and strengthening its balance sheet.
The move signals continued capital markets activity by Imugene as it funds its immuno-oncology pipeline and engages investors through derivative securities. While the immediate impact is primarily on the company’s capital structure and potential dilution, the enlarged pool of listed options could enhance liquidity in Imugene’s securities and offer existing and new stakeholders leveraged exposure to the company’s future performance.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company listed on the ASX that focuses on developing immuno-oncology therapies. The company operates in the life sciences and healthcare sector, leveraging advanced biological platforms to create treatments targeting cancer and related diseases for global markets.
YTD Price Performance: -69.86%
Average Trading Volume: 1,554,949
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$45.74M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.